These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 21805352)

  • 1. Interaction potential of the endothelin-A receptor antagonist atrasentan with drug transporters and drug-metabolising enzymes assessed in vitro.
    Weiss J; Haefeli WE
    Cancer Chemother Pharmacol; 2011 Oct; 68(4):1093-8. PubMed ID: 21805352
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Obatoclax as a perpetrator in drug-drug interactions and its efficacy in multidrug resistance cell lines.
    Theile D; Allendorf D; Köhler BC; Jassowicz A; Weiss J
    J Pharm Pharmacol; 2015 Nov; 67(11):1575-84. PubMed ID: 26255619
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Telaprevir is a substrate and moderate inhibitor of P-glycoprotein, a strong inductor of ABCG2, but not an activator of PXR in vitro.
    Weiss J; Becker JP; Haefeli WE
    Int J Antimicrob Agents; 2014 Feb; 43(2):184-8. PubMed ID: 24332840
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interaction of thiazolidinediones (glitazones) with the ATP-binding cassette transporters P-glycoprotein and breast cancer resistance protein.
    Weiss J; Sauer A; Herzog M; Böger RH; Haefeli WE; Benndorf RA
    Pharmacology; 2009; 84(5):264-70. PubMed ID: 19776663
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potential of the novel antiretroviral drug rilpivirine to modulate the expression and function of drug transporters and drug-metabolising enzymes in vitro.
    Weiss J; Haefeli WE
    Int J Antimicrob Agents; 2013 May; 41(5):484-7. PubMed ID: 23428312
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Flavonoids inhibit breast cancer resistance protein-mediated drug resistance: transporter specificity and structure-activity relationship.
    Katayama K; Masuyama K; Yoshioka S; Hasegawa H; Mitsuhashi J; Sugimoto Y
    Cancer Chemother Pharmacol; 2007 Nov; 60(6):789-97. PubMed ID: 17345086
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro investigations into the roles of drug transporters and metabolizing enzymes in the disposition and drug interactions of dolutegravir, a HIV integrase inhibitor.
    Reese MJ; Savina PM; Generaux GT; Tracey H; Humphreys JE; Kanaoka E; Webster LO; Harmon KA; Clarke JD; Polli JW
    Drug Metab Dispos; 2013 Feb; 41(2):353-61. PubMed ID: 23132334
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro characterization of axitinib interactions with human efflux and hepatic uptake transporters: implications for disposition and drug interactions.
    Reyner EL; Sevidal S; West MA; Clouser-Roche A; Freiwald S; Fenner K; Ullah M; Lee CA; Smith BJ
    Drug Metab Dispos; 2013 Aug; 41(8):1575-83. PubMed ID: 23729661
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reversal of different drug-resistant phenotypes by an autocatalytic multitarget multiribozyme directed against the transcripts of the ABC transporters MDR1/P-gp, MRP2, and BCRP.
    Kowalski P; Surowiak P; Lage H
    Mol Ther; 2005 Apr; 11(4):508-22. PubMed ID: 15771954
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro and in vivo evaluation of WK-X-34, a novel inhibitor of P-glycoprotein and BCRP, using radio imaging techniques.
    Jekerle V; Klinkhammer W; Scollard DA; Breitbach K; Reilly RM; Piquette-Miller M; Wiese M
    Int J Cancer; 2006 Jul; 119(2):414-22. PubMed ID: 16646006
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reversal of P-gp and BCRP-mediated MDR by tariquidar derivatives.
    Li XQ; Wang L; Lei Y; Hu T; Zhang FL; Cho CH; To KK
    Eur J Med Chem; 2015 Aug; 101():560-72. PubMed ID: 26197160
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of LW6 as a new potent inhibitor of breast cancer resistance protein.
    Song JG; Lee YS; Park JA; Lee EH; Lim SJ; Yang SJ; Zhao M; Lee K; Han HK
    Cancer Chemother Pharmacol; 2016 Oct; 78(4):735-44. PubMed ID: 27520631
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytochrome p450 inhibitory properties of common efflux transporter inhibitors.
    Englund G; Lundquist P; Skogastierna C; Johansson J; Hoogstraate J; Afzelius L; Andersson TB; Projean D
    Drug Metab Dispos; 2014 Mar; 42(3):441-7. PubMed ID: 24396142
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A new intestinal cell culture model to discriminate the relative contribution of P-gp and BCRP on transport of substrates such as imatinib.
    Graber-Maier A; Gutmann H; Drewe J
    Mol Pharm; 2010 Oct; 7(5):1618-28. PubMed ID: 20701289
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interaction of angiotensin receptor type 1 blockers with ATP-binding cassette transporters.
    Weiss J; Sauer A; Divac N; Herzog M; Schwedhelm E; Böger RH; Haefeli WE; Benndorf RA
    Biopharm Drug Dispos; 2010 Mar; 31(2-3):150-61. PubMed ID: 20222053
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gefitinib modulates the function of multiple ATP-binding cassette transporters in vivo.
    Leggas M; Panetta JC; Zhuang Y; Schuetz JD; Johnston B; Bai F; Sorrentino B; Zhou S; Houghton PJ; Stewart CF
    Cancer Res; 2006 May; 66(9):4802-7. PubMed ID: 16651435
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ixabepilone, a novel microtubule-targeting agent for breast cancer, is a substrate for P-glycoprotein (P-gp/MDR1/ABCB1) but not breast cancer resistance protein (BCRP/ABCG2).
    Shen H; Lee FY; Gan J
    J Pharmacol Exp Ther; 2011 May; 337(2):423-32. PubMed ID: 21262849
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The potential of Sutherlandia frutescens for herb-drug interaction.
    Fasinu PS; Gutmann H; Schiller H; James AD; Bouic PJ; Rosenkranz B
    Drug Metab Dispos; 2013 Feb; 41(2):488-97. PubMed ID: 23209194
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potential of novel antiretrovirals to modulate expression and function of drug transporters in vitro.
    Zembruski NC; Büchel G; Jödicke L; Herzog M; Haefeli WE; Weiss J
    J Antimicrob Chemother; 2011 Apr; 66(4):802-12. PubMed ID: 21393174
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of aripiprazole and its active metabolite dehydroaripiprazole on the activities of drug efflux transporters expressed both in the intestine and at the blood-brain barrier.
    Nagasaka Y; Oda K; Iwatsubo T; Kawamura A; Usui T
    Biopharm Drug Dispos; 2012 Sep; 33(6):304-15. PubMed ID: 22847220
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.